Tirabrutinib + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Central Nervous System Lymphoma
Conditions
Primary Central Nervous System Lymphoma
Trial Timeline
Oct 6, 2023 → Feb 1, 2030
NCT ID
NCT06940791About Tirabrutinib + Placebo
Tirabrutinib + Placebo is a phase 2 stage product being developed by Ono Pharmaceutical for Primary Central Nervous System Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06940791. Target conditions include Primary Central Nervous System Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06940791 | Phase 2 | Recruiting |
| NCT02626026 | Phase 1 | Completed |
Competing Products
20 competing products in Primary Central Nervous System Lymphoma